Invivyd, INC 10-Q quarterly reports

Invivyd, Inc. filed its Q1 2026 10-Q report, detailing a net loss of $41.4 million and continued investment in its VYD2311 COVID-19 program.

Invivyd, a biopharmaceutical company, reported significantly reduced net losses and increased product revenue in Q3 2025, while advancing its VYD2311 COVID-19 prevention program with positive FDA feedback.

Invivyd, Inc. reported a significantly reduced net loss in the second quarter of 2025, driven by increased PEMGARDA sales, while advancing its next-generation COVID-19 antibody, VYD2311, towards potential BLA approval.

Invivyd, Inc. reports its first quarter 2025 financial results, including $11.3 million in product revenue, but expresses substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows.

Invivyd, Inc. reported its third quarter 2024 financial results, highlighting revenue from PEMGARDA sales and progress in clinical development of its next-generation antibody candidate.

Invivyd, Inc. reports its first product revenue following emergency use authorization for PEMGARDA, while also disclosing substantial doubt about its ability to continue as a going concern.

Invivyd, Inc. announced its first quarter 2024 results, highlighting the emergency use authorization (EUA) for PEMGARDA and the advancement of its pipeline.